{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:17:49Z","timestamp":1763018269605,"version":"3.37.3"},"reference-count":17,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,11,8]],"date-time":"2020-11-08T00:00:00Z","timestamp":1604793600000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There are significant risks of parenteral prostacyclin use in patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), which may limit their use. Selexipag is an oral, selective prostacyclin analogue that has been shown to reduce disease progression and improve exercise capacity in patients with PAH-CHD. Administering Selexipag in patients with PAH-CHD could potentially overcome some of the risks of parenteral therapy while improving clinical outcomes.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Case summary<\/jats:title>\n                  <jats:p>We report five cases highlighting the clinical uses of Selexipag in patients with PAH-CHD. In the first two cases, Selexipag was initiated as part of a Treat-to-close strategy. In the third case, initiation of Selexipag improved symptoms and objective exercise capacity in a patient with Eisenmenger syndrome. In the fourth and fifth cases, rapid cross-titration protocols were used to transition from parenteral prostacyclins to Selexipag. In the fourth case, Selexipag was initiated in the context of significant side effects limiting parenteral prostacyclin use. In the fifth case, Selexipag was used to down-titrate from parenteral prostacyclins following closure of a sinus venosus atrial septal defect and redirection of anomalous pulmonary veins.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Discussion<\/jats:title>\n                  <jats:p>Selexipag is a promising oral therapy for patients with at various stages of the spectrum of PAH-CHD to improve symptoms, exercise capacity and, in some cases, haemodynamics. Our cases also highlight practical aspects of Selexipag use including targeting the individualized maximally tolerated dose for each patient, managing side effects and managing dose interruptions.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcr\/ytaa320","type":"journal-article","created":{"date-parts":[[2020,11,7]],"date-time":"2020-11-07T21:01:41Z","timestamp":1604782901000},"page":"1-7","source":"Crossref","is-referenced-by-count":4,"title":["Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series"],"prefix":"10.1093","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2465-1487","authenticated-orcid":false,"given":"Sarah","family":"Blissett","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, L524, UCSF Box 0103, San Francisco, CA 94117, USA"},{"name":"Division of Cardiology, Department of Medicine, Western University, 339 Windermere Rd, London, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Blusztein","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, L524, UCSF Box 0103, San Francisco, CA 94117, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6354-1873","authenticated-orcid":false,"given":"Vaikom S","family":"Mahadevan","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, University of California San Francisco, 505 Parnassus Avenue, L524, UCSF Box 0103, San Francisco, CA 94117, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,11,7]]},"reference":[{"key":"2021010812213549900_ytaa320-B1","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"2021010812213549900_ytaa320-B2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1471-2466-14-45","article-title":"Epidemiology and long-term survival of pulmonary arterial hypertension in the Czech Republic: a retrospective analysis of a nationwide registry","volume":"14","author":"Jansa","year":"2014","journal-title":"BMC Pulm Med"},{"key":"2021010812213549900_ytaa320-B3","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.2165\/00003495-200868080-00004","article-title":"Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger\u2019s syndrome","volume":"68","author":"Galie","year":"2008","journal-title":"Drugs"},{"key":"2021010812213549900_ytaa320-B4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.recesp.2016.01.002","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"69","author":"Gali\u00e8","year":"2016","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"2021010812213549900_ytaa320-B5","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"2021010812213549900_ytaa320-B6","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1002\/ejhf.1375","article-title":"Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study","volume":"21","author":"Beghetti","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2021010812213549900_ytaa320-B7","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.amjcard.2013.07.027","article-title":"Usefulness of medical therapy for pulmonary hypertension and delayed atrial septal defect closure","volume":"112","author":"Bradley","year":"2013","journal-title":"Am J Cardiol"},{"key":"2021010812213549900_ytaa320-B8","doi-asserted-by":"crossref","first-page":"E714","DOI":"10.1097\/MJT.0000000000000727","article-title":"Selexipag in congenital heart disease-associated pulmonary arterial hypertension and Eisenmenger syndrome: first report","volume":"25","author":"El-Kersh","year":"2018","journal-title":"Am J Ther"},{"key":"2021010812213549900_ytaa320-B9","doi-asserted-by":"crossref","first-page":"204589401983219","DOI":"10.1177\/2045894019832199","article-title":"Real-life data on Selexipag for the treatment of pulmonary hypertension","volume":"9","author":"Barnikel","year":"2019","journal-title":"Pulm Circ"},{"key":"2021010812213549900_ytaa320-B10","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.2146\/ajhp170814","article-title":"Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series","volume":"75","author":"Fanous","year":"2018","journal-title":"Am J Heal Pharm"},{"key":"2021010812213549900_ytaa320-B11","doi-asserted-by":"crossref","first-page":"1902418","DOI":"10.1183\/13993003.02418-2019","article-title":"Transition from intravenous epoprostenol to selexipag in pulmonary arterial hypertension: a word of caution","volume":"55","author":"Yanaka","year":"2020","journal-title":"Eur Respir J"},{"key":"2021010812213549900_ytaa320-B12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.healun.2018.09.003","article-title":"Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: results from the TRANSIT-1 study","volume":"38","author":"Frost","year":"2019","journal-title":"J Hear Lung Transplant"},{"key":"2021010812213549900_ytaa320-B13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12890-017-0480-9","article-title":"Successful transition from Treprostinil to Selexipag in patient with severe pulmonary arterial hypertension","volume":"17","author":"Furukawa","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2021010812213549900_ytaa320-B14","doi-asserted-by":"crossref","first-page":"2045894019862167","DOI":"10.1177\/2045894019862167","article-title":"Transition from parental prostacyclin to selexipag: a case series of five pulmonary arterial hypertension patients","volume":"9","author":"Holthaus","year":"2019","journal-title":"Pulm Circ"},{"key":"2021010812213549900_ytaa320-B15","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"N Engl J Med"},{"key":"2021010812213549900_ytaa320-B16","doi-asserted-by":"crossref","first-page":"H1235","DOI":"10.1152\/ajpheart.00254.2009","article-title":"Genomewide RNA expression profiling in lung identifies distinct signatures in idiopathic pulmonary arterial hypertension and secondary pulmonary hypertension","volume":"298","author":"Rajkumar","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2021010812213549900_ytaa320-B17","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.healun.2017.09.024","article-title":"Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study","volume":"37","author":"Preston","year":"2018","journal-title":"J Hear Lung Transplant"}],"container-title":["European Heart Journal - Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/4\/6\/1\/35545390\/ytaa320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcr\/article-pdf\/4\/6\/1\/35545390\/ytaa320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T23:53:07Z","timestamp":1610581987000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcr\/article\/4\/6\/1\/5960196"}},"subtitle":[],"editor":[{"given":"Sylvia","family":"Krupickova","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Inga","family":"Voges","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Filippo","family":"Puricelli","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Rahul","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Vassilios Parisis","family":"Memtsas","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,7]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,11,7]]},"published-print":{"date-parts":[[2020,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcr\/ytaa320","relation":{},"ISSN":["2514-2119"],"issn-type":[{"type":"electronic","value":"2514-2119"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,11,7]]}}}